Physician profile
Lynnelle Cain
NPI 1487746004
$638.11
in general payments reported to CMS, 2019-2025
19 companies · $134 in 2025
The $134 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $36.12 · 2023: $342 · 2024: $126 · 2025: $134.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $602.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $601.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $124.60 | 2023-2025 | Mounjaro, Jardiance |
| Glaxosmithkline, LLC. | $95.83 | 2023-2025 | Trelegy Ellipta, Shingrix |
| Abbvie INC. | $51.56 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $44.03 | 2023-2024 | Farxiga, Fasenra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $44.00 | 2021-2023 | Jardiance |
| Novartis Pharmaceuticals Corporation | $36.06 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $27.49 | 2024 | |
| Sage Therapeutics, LLC | $24.12 | 2024 | |
| Otsuka America Pharmaceutical, INC. | $21.67 | 2023 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $21.46 | 2023 | |
| Ultragenyx Pharmaceutical INC. | $20.42 | 2023 | |
| Sumitomo Pharma America, INC. | $20.06 | 2023 | Gemtesa |
| Insulet Corporation | $19.30 | 2025 | Omnipod |
| Boston Scientific Corporation | $19.00 | 2023 | Watchman Access System |
| Novo Nordisk INC | $18.08 | 2023 | Ozempic, Rybelsus |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $17.22 | 2025 | Lifevest |
| Merck Sharp & Dohme LLC | $13.79 | 2023 | Verquvo |
| Neurelis, INC. | $13.27 | 2024 | Valtoco |
| Genentech USA, INC. | $6.15 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lynnelle Cain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.